Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597695 · ClinicalTrials.gov registry record · Phase 1
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
A Phase 1 study of Depression, sponsored by Juliana Zambrano, MD, MPH.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06597695: Recruiting Phase 1 study of Depression, sponsored by Juliana Zambrano, MD, MPH.
NCT06597695 is a Phase 1 study of Depression that is actively recruiting participants, run by Juliana Zambrano, MD, MPH. The registered enrollment target is 10 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06597695, a Phase 1 study of Depression, is actively recruiting participants, sponsored by Juliana Zambrano, MD, MPH.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
Primary Outcome
(a) Assess the attendance and adherence rates of participants to the group-based ketamine intervention sessions; (b) Evaluate the feasibility of delivering the intervention sessions as planned, including the preparatory, dosing, and integration sessions; (c) Explore the perceptions and experiences of Spanish-speaking participants regarding the intervention.
Conditions Studied
Interventions
- DRUG Ketamine-assisted psychotherapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital, Chelsea - Chelsea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
What NCT06597695 shows while recruiting
NCT06597695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Ketamine-assisted psychotherapy is the first listed.
NCT06597695 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06597695 about?
NCT06597695 is a clinical study titled "A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression". This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
What is the current status of trial NCT06597695?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-07-23. Estimated completion is 2026-07-01.
What conditions does trial NCT06597695 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06597695?
The interventions under investigation include: Ketamine-assisted psychotherapy (DRUG).
Who is sponsoring clinical trial NCT06597695?
This trial is sponsored by Juliana Zambrano, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597695 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06597695's enrollment target sits among peer trials
10 659th of 679 higher than 17 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy